Skip to content
Open access · OA via OpenAlex

Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases

Philipp J. Kahle, Christian Haass, Hans A. Kretzschmar, Manuela Neumann

Journal of Neurochemistry · 2002 · ▲ 87 citations

Abstract

α-Synuclein (αSYN) was originally identified in the electric organ of the electric eel Torpedo californica ( Maroteaux et al. 1988 ). It is now well documented that αSYN and its close homolog βSYN are abundantly expressed in presynaptic terminals of vertebrates. Experimental down-regulation of αSYN in knock-out mice and in primary neurones suggests that αSYN regulates synaptic neurotransmission, but the molecular mechanism is still poorly understood. A breakthrough was achieved when two different mutations in the αSYN gene were identified in autosomal-dominant hereditary Parkinson's disease (PD) patients. Soon thereafter, αSYN was found to be the major protein component in the hallmark lesions of PD [Lewy bodies (LBs) and Lewy neurites]. Lewy pathology is also characteristic for dementia with LBs (DLB), the LB variant of Alzheimer's disease, and neurodegeneration with brain iron accumulation type 1 (formerly known as Hallervorden–Spatz disease). Moreover, αSYN fibrils are deposited in (oligodendro)glial cytoplasmic inclusions (GCIs) of multiple system atrophy (MSA) patients. α-Synuclein specifically has an intrinsic propensity to form fibrils in vitro. PD-associated mutations and oxidative stress enhance αSYN aggregation. During fibril formation, the naturally unfolded αSYN undergoes conformational changes, transiently existing as a partially folded intermediate and protofibril. It is a matter of intense research to establish whether the folding intermediates and/or the LB fibrils exert neurotoxicity in human patients. To better understand the pathophysiology of αSYN, a number of transgenic animal models have been developed. Expression of human αSYN in Drosophila melanogaster caused age-dependent, dopamine-selective neurodegeneration and the formation of LB-like deposits. A variety of promoters have been used to express transgenic αSYN in mice. Aberrant accumulation of αSYN in cell bodies and swollen neurites were common observations. Some models displayed age-dependent enhancement of phenotype, such as formation of ubiquitin-positive inclusions, loss of dopaminergic synapses and locomotor deficits. Of great relevance are recent reports that amyloid seeded αSYN aggregation, whereas the non-amyloidogenic βSYN inhibited αSYN fibril formation both in vitro and in vivo. Still, additional genetic and/or environmental risk factors need to be considered in order to generate a complete mouse model of PD. The synucleins comprise a family of 15–20-kDa proteins including αSYN, βSYN and γSYN (also termed persyn) (Kahle et al. 2000a). The primary sequences span three regions (Fig. 1a). The amino-terminal half is characterized by five or six imperfectly conserved repeats (EKTKEGV, single-letter code). This region acquires α-helical secondary structure upon lipid binding (Eliezer et al. 2001), whereas the less conserved carboxy-terminus, in which acidic amino acid side chains are clustered, is highly flexible (Eliezer et al. 2001). A stretch of amino acids critically involved in αSYN aggregation (Giasson et al. 2001; Kahle et al. 2001) resides in the central, hydrophobic portion (called non-amyloid component [NAC]). (a) Schematic representation of synucleins. The imperfect KTKEGV repeats are numbered, the 6th repeat missing in βSYN is stippled. (b and c) Kyte–Doolittle hydropathy plots of αSYN (b) and βSYN (c). The NAC domain amino acid sequences are aligned in the middle, and are indicated by black boxes under each hydropathy plot. The natural deletion in βSYN is stippled. (dand e) Cortical LBs in the temporal cortex (arrows) in a DLB case showing strong αSYN immunoreactivity (d), but no labeling for βSYN (e). The absence of βSYN immunoreactivity in an LB (arrow) displacing a neuronal nucleus (arrowhead) is featured in the insert. The amino-terminal repeats of αSYN were predicted to form an α-helical structure similar to the lipid-binding domains of class A2 apolipoproteins (Davidson et al. 1998). Indeed, αSYN tightly binds to synthetic phospholipid vesicles, and preferentially binds to those with acidic head groups (Davidson et al. 1998; Jo et al. 2000). Mutational analysis of lipid-binding determinants (Perrin et al. 2000) revealed that the lipid-binding domain was broadly distributed over the amino-terminal half of αSYN. Amphipathic class A2 helix formation was crucial because replacement of the six amino-terminal threonines (predicted to lie along the hydrophobic face of the helix) with charged amino acids disrupted binding of mutant αSYN with vesicles. Recombinant full-length, but not amino-terminally truncated αSYN interacted with a crude membrane fraction from rat brain (Jensen et al. 1998). Both PD-associated mutations (A53T, Polymeropoulos et al. 1997; A30P, Krüger et al. 1998) reside in the lipid-binding amino-terminus of αSYN (Fig. 1a). The A30P mutation abolishes a helical moment in the amino-terminus (Bussell and Eliezer 2001), and was reported to disrupt αSYN binding to rat brain membranes (Jensen et al. 1998). The effect on binding to synthetic membranes was much less marked (Perrin et al. 2000; Narayanan and Scarlata 2001). In transfected cortical neurone cultures, PD mutations did not affect coupling of αSYN to lipophilic dyes (McLean et al. 2000). When transgenic mouse brain expressing human mutant [A30P]αSYN was subjected to sucrose gradient floatation experiments (Jensen et al. 1998), the mutant protein was found in the soluble as well as in the floating fractions, as was the endogenous αSYN (Kahle et al. 2000b). Thus, it is unlikely that αSYN mutations cause PD as a result of a loss of membrane binding. Subcellular fractionation of rat, mouse and human brain revealed that αSYN and βSYN were enriched in the synaptosomal fractions, but were dissociated from the synaptic vesicles (SVs) upon further purification (Maroteaux and Scheller 1991; Shibayama-Imazu et al. 1993; George et al. 1995; Kahle et al. 2000b). Thus, the interactionof synucleins with SVs appears to be reversible. Phosp

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1046/j.1471-4159.2002.01020.x
Canonical
link ↗
Fetched
2026-10-21 MST

Cite this

APA
Kahle, P.J., Haass, C., Kretzschmar, H.A., &amp; Neumann, M. (2002). Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. <em>Journal of Neurochemistry</em>. https://doi.org/10.1046/j.1471-4159.2002.01020.x
Vancouver
Kahle PJ, Haass C, Kretzschmar HA, Neumann M. Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. Journal of Neurochemistry. 2002. doi:10.1046/j.1471-4159.2002.01020.x.
BibTeX
@article{philipp2002Struct, title = {Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases}, author = {Philipp J. Kahle and Christian Haass and Hans A. Kretzschmar and Manuela Neumann}, journal = {Journal of Neurochemistry}, year = {2002}, doi = {10.1046/j.1471-4159.2002.01020.x}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings